References
- Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;13:581-92.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. Cancer J Clin 2009;59:225-49.
- Héry C, Ferlay J, Boniol M, et al. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008;19:1187-94.
- Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
- Cancer Research UK. Breast cancer – UK mortality statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/breast/mortality/index.htm [Last accessed May 2010]
- Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-25.
- Kataja V, Catiglione M, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii11-13.
- Brodie AM, Njar VC. Aromatase inhibitors and their application in breast cancer treatment. Steroids 2000;65:171-9.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. V.2.2010. Available at: www.nccn.org [Last accessed May 2010]
- Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4-13.
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
- Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
- Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007;109:1721-8.
- Huang HJ, Neven P, Drijkoningen M, et al. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005;91:81-7.
- Hartley MC, McKinley BP, Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (< or ≥40) breast cancer patients: a case–control study. Am Surg 2006;72:1189-94.
- Pronzato P, Mustacchi G, De Matteis A, et al. Biological characteristics and medical treatment of breast cancer in young women – a featured population: results from the NORA study. Int J Breast Cancer 2011;2011:534256.
- Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7.
- Caldarella A, Crocetti E, Bianchi S, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 2011;17:753-8.
- Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2008;112:53-66.
- Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009;14:645-56.
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
- Nahta R, Shabaya S, Ozbay T, et al. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med 2009;7:263-74.